The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages 812-819

  Seinen, M L ^a   van Asseldonk, D P ^a   de Boer, N K H ^a   Losekoot, N ^a   Smid, K ^a   Mulder, C J J ^a   Bouma, G ^a   Peters, G J ^a   van Bodegraven, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allopurinol; Azathioprine; Hypoxanthine guanine phosphoribosyl transferase; Inflammatory bowel disease; Thiopurine methyl transferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CROHN DISEASE; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME METABOLISM; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; MALAISE; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

ALLOPURINOL; AZATHIOPRINE; HYPOXANTHINE GUANINE PHOSPHORIBOSYL TRANSFERASE; INFLAMMATORY BOWEL DISEASE; THIOPURINE METHYL TRANSFERASE;

6-MERCAPTOPURINE; ADULT; ALLOPURINOL; AZATHIOPRINE; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FATIGUE; FEMALE; GUANINE NUCLEOTIDES; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; THIOINOSINE; THIONUCLEOTIDES; XANTHINE OXIDASE;

EID: 84884142037     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.12.006     Document Type: Article

References (42)

1. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
2. Jharap B., Seinen M.L., de Boer N.K., van Ginkel J.R., Linskens R.K., Kneppelhout J.C., et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010 Sep, 16(9):1541-1549.
3. van Asseldonk D.P., de Boer N.K., Peters G.J., Veldkamp A.I., Mulder C.J., van Bodegraven A.A. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab 2009, 10:981-997.
4. van Asseldonk D.P., Sanderson J., de Boer N.K., Sparrow M.P., Lemann M., Ansari A., et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-Proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis 2011 Apr, 43(4):270-276.
5. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
6. Osterman M.T., Kundu R., Lichtenstein G.R., Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
7. Hindorf U., Lindqvist M., Peterson C., Soderkvist P., Strom M., Hjortswang H., et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006, 55:1423-1431.
8. Roblin X., Peyrin-Biroulet L., Phelip J.M., Nancey S., Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008, 103:3115-3122.
9. Gonzalez-Lama Y., Bermejo F., Lopez-Sanroman A., Garcia-Sanchez V., Esteve M., Cabriada J.L., et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011, 34:544-554.
10. Reinshagen M., Schutz E., Armstrong V.W., Behrens C., von Tirpitz C., Stallmach A., et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007, 53:1306-1314.
11. Chocair P., Duley J., Simmonds H.A., Cameron J.S., Ianhez L., Arap S., et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993, 342:83-84.
12. Sparrow M.P., Hande S.A., Friedman S., Lim W.C., Reddy S.I., Cao D., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441-446.
13. Gardiner S.J., Gearry R.B., Burt M.J., Chalmers-Watson T., Chapman B.A., Ross A.G., et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 2011, 26:49-54.
14. Govani S.M., Higgins P.D. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010, 4:444-449.
15. Kennedy N.A., Asser T.L., Mountifield R.E., Doogue M.P., Andrews J.M., Bampton P.A. Thiopurine metabolite measurement leads to changes in management of Inflammatory Bowel Disease. Intern Med J 2012 Sep 5, Epub ahead of print.
16. Smith M.A., Blaker P., Marinaki A.M., Anderson S.H., Irving P.M., Sanderson J.D. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012, 6:905-912.
17. Ansari A., Patel N., Sanderson J., O'Donohue J., Duley J.A., Florin T.H. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:640-647.
18. Hoentjen F., Seinen M.L., Hanauer S.B., de Boer N.K., Rubin D.L., Bouma G., et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2012 May 17, Epub ahead of print.
19. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6.
20. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010, 4:28-62.
21. de Graaf P., Vos R.M., de Boer N.H., Sinjewel A., Jharap B., Mulder C.J., et al. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:1437-1442.
22. Dervieux T., Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem 1998, 44:2511-2515.
23. Lennard L., Singleton H.J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992, 583:83-90.
24. Shipkova M., Armstrong V.W., Wieland E., Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003, 49:260-268.
25. Seinen M.L., de Boer N.K., Smid K., van Asseldonk D.P., Bouma G., van Bodegraven A.A., et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 2011, 30:1085-1090.
26. Tax W.J., Veerkamp J.H., Trijbels J.M. Activity of purine phosphoribosyltransferases and of two enzymes of pyrimidine biosynthesis in erythrocytes of ten mammalian species. Comp Biochem Physiol B 1976, 54:209-212.
27. Peters G.J., Veerkamp J.H. Concentration, synthesis and utilization of phosphoribosylpyrophosphate in lymphocytes of five mammalian species. Int J Biochem 1979, 10:885-888.
28. Keizer-Garritsen J.J., Brouwer C., Lambooy L.H., Ter Riet P., Bokkerink J.P., Trijbels F.J., et al. Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. Ann Clin Biochem 2003, 40:86-93.
29. Sparrow M.P., Hande S.A., Friedman S., Cao D., Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209-214.
30. van Asseldonk D.P., de Boer N.K., Smid K., Mulder C.J., van Bodegraven A.A., Peters G.J. Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy. Nucleosides Nucleotides Nucleic Acids 2010, 29:284-290.
31. Ding L., Zhang F.B., Liu H., Gao X., Bi H.C., Wang X.D., et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2012 Jan, 18(1):63-73.
32. Ansari A., Aslam Z., De Sica A., Smith M., Gilshenan K., Fairbanks L., et al. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 2008, 28:749-757.
33. Duley J.A., Chocair P.R., Florin T.H. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 2005, 22:1161-1162.
34. Deininger M., Szumlanski C.L., Otterness D.M., Van Loon J., Ferber W., Weinshilboum R.M. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994, 48:2135-2138.
35. Blaker P.A., Arenas M., Fairbanks L. A biochemical mechanism for the role of allopurinol in TPMT inhibition. Gut 2011, 60(Suppl. 1):A122-3.
36. Ansari A., Elliott T., Baburajan B., Mayhead P., O'Donohue J., Chocair P., et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:734-741.
37. Roberts R.L., Gearry R.B., Barclay M.L. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?. Pharmacogenomics 2010, 11:1505-1508.
38. Haglund S., Vikingsson S., Soderman J., Hindorf U., Granno C., Danelius M., et al. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease. Ther Drug Monit 2011, 33:200-208.
39. Roberts R.L., Gearry R.B., Barclay M.L., Kennedy M.A. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007, 7:312-317.
40. Bakker J.A., Lindhout M., Habets D.D., van den Wijngaard A., Paulussen A.D., Bierau J. The effect of ITPA polymorphisms on the enzyme kinetic properties of human erythrocyte inosine triphosphatase toward its substrates ITP and 6-Thio-ITP. Nucleosides Nucleotides Nucleic Acids 2011, 30:839-849.
41. Ansari A., Arenas M., Greenfield S.M., Morris D., Lindsay J., Gilshenan K., et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:973-983.
42. Marinaki A.M., Ansari A., Duley J.A., Arenas M., Sumi S., Lewis C.M., et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14:181-187.